Health Care & Life Sciences » Pharmaceuticals | Knight Therapeutics Inc.

Knight Therapeutics Inc. | Mutual Funds

Mutual Funds that own Knight Therapeutics Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
CI Cambridge Canadian Equity Corporate Class
3,500,000
2.45%
0
0.59%
06/30/2017
Fidelity True North Fund
2,725,000
1.91%
325,000
0.49%
07/31/2018
Janus Venture Fund
2,572,196
1.8%
0
0.46%
06/30/2018
IA Clarington Canadian Small Cap Fund
2,520,460
1.77%
0
2.2%
08/31/2018
Fidelity Canadian Growth Company Fund
2,265,300
1.59%
0
0.36%
07/31/2018
Cambridge Canadian Asset Allocation Corporate Class
1,850,000
1.3%
0
0.33%
06/30/2017
London Life Mid Cap Canada Fund (GWLIM)
1,610,537
1.12%
67,927
1.74%
12/31/2017
Fidelity Special Situations Fund
1,298,300
0.91%
0
0.47%
07/31/2018
National Bank Canadian All Cap Equity Fund
1,250,327
0.88%
7,996
1.25%
12/31/2017
British Columbia Inv Management Corp.
1,230,589
0.86%
471,850
0.01%
03/31/2017

About Knight Therapeutics

View Profile
Address
3400, de Maisonneuve Boulevard West
Montréal Québec H3Z 3B8
Canada
Employees -
Website http://www.gud-knight.com
Updated 07/08/2019
Knight Therapeutics Inc engages in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. It offers commercialized Rx and over-the-counter products, which includes Impavido, Movantik, ATryn, and AzaSite. The company was founded by Jonathan Ross Goodman on November 1, 2013 and is headquartered in Montreal, Canada.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.